Central nervous system melanoma

2 trials MedDRA PT
2 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-1) 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Pfizer Inc. Commercial
    PEMBROLIZUMAB
    2024-512038-13-00 11 countries 2021 n=161
    Ended

Phase II

1 trial
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509471-17-00 5 countries 2023 n=119
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 2 Phase II, Phase III 0
New trials by year
2021
1
2023
1
← All indication landscapes